| Chen, Yundai |
Health, NCT06187727: Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction |
|
|
| Recruiting | 4 | 240 | RoW | Henagliflozin | Qian geng | Myocardial Infarction, Heart Failure | 10/24 | 10/24 | | |
NCT02698839: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 539 | RoW | BuMA Supreme, BuMA™ | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 03/18 | 12/25 | | |
OPC, NCT02698852: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 1000 | RoW | BuMA Supreme | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 05/19 | 12/25 | | |
NCT04220437: Identification of Neoatherosclerosis in ISR Patients Based on Artifical Intelligence |
|
|
| Recruiting | N/A | 90 | RoW | no interventin | Chinese PLA General Hospital | In-stent Restenosis, Neo-atherosclerosis, Retrospective | 01/21 | 02/21 | | |
NCT03574636: OCT vs IVUS vs QCA to Guide Moderate-to-severe Calcified Lesion Stent Implantation |
|
|
| Recruiting | N/A | 375 | RoW | OCT guidance, IVUS guidance, QCA | Shanghai MicroPort Medical (Group) Co., Ltd. | Optical Coherence Tomography, Intravascular Ultrasound, Angiography | 09/21 | 09/25 | | |
SUPERIOR, NCT04617899: The StUdy to Evaluate the Performance and safEty of the Novasight HybRid System Using Objective PeRformance Criteria |
|
|
| Recruiting | N/A | 120 | RoW | Intravascular imaging | CardioNavi MedTech (Wuhan) Co., Ltd., Beijing Jingruitianhe Medical Science and Technology Development Co,Ltd | Coronary Artery Disease | 11/21 | 12/21 | | |
NCT04733443: The Safety and Efficacy of Biolimus in the Treatment of Patients With in Stent Restenosis |
|
|
| Active, not recruiting | N/A | 310 | RoW | Biolimus, SeQuent® Please Neo | JW Medical Systems Ltd | Coronary Artery Disease | 01/23 | 02/25 | | |
| Active, not recruiting | N/A | 52 | RoW | Medtronic CoreValve™ Evolut™ PRO System | Medtronic Cardiovascular | Severe, Symptomatic Aortic Stenosis | 03/23 | 05/28 | | |
| Recruiting | N/A | 120 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Regurgitation Disease | 05/23 | 05/24 | | |
NCT05607667: Clinical Trial in China for Aortic Valve Stenosis |
|
|
| Recruiting | N/A | 53 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Stenosis Disease | 05/23 | 05/23 | | |
NCT04722796: HANGZHOU Solution in Bicuspid AS Undergoing TAVR |
|
|
| Recruiting | N/A | 508 | RoW | TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution), Hangzhou solution, TAVR with Venus A plus using annular sizing and THV implantation technique, Traditional sizing strategy (Annulus based sizing strategy) | Second Affiliated Hospital, School of Medicine, Zhejiang University, Venus MedTech (HangZhou) Inc., First Affiliated Hospital Bengbu Medical College, Chinese PLA General Hospital, Fujian Medical University Union Hospital, Xiamen University Affiliated Cardiovascular Hospital, Guangdong People's Hospital, Zhengzhou Cardiovascular Hospital, The First Affiliated Hospital of Zhengzhou University, Hennan Provincial Chest Hospital, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Central South University, Northern Jiangsu Province People's Hospital, The First Affiliated Hospital of Nanchang University, Second Affiliated Hospital of Nanchang University, The Affiliated Hospital of Qingdao University, Shanxi cardiovascular hospital, Tianjin Chest Hospital, Ning Bo First Hospital | Aortic Stenosis, Aortic Stenosis With Bicuspid Valve | 04/24 | 04/28 | | |
NCT05454878: Atrial Fibrillation Monitoring on Patients With Lymphoma After Chemotherapy |
|
|
| Not yet recruiting | N/A | 100 | RoW | | Chinese PLA General Hospital | Atrial Fibrillation | 07/23 | 12/23 | | |
| Zhou, Huanfen |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
NCT03586557: Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis |
|
|
| Recruiting | N/A | 142 | RoW | Corticosteroid & Plasma exchange, CS+PE, Corticosteroid, CS | Chinese PLA General Hospital | Optic Neuritis | 12/21 | 12/21 | | |
| Liang, Beibei |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
NCT04620408: Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers |
|
|
| Not yet recruiting | 1 | 14 | NA | SHR4640 | Jiangsu HengRui Medicine Co., Ltd. | Healthy Subjects | 01/21 | 02/21 | | |
